Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06896201

Comfortage - AD Prevention Strategies

Study is Interventional, cross-sectional, clinical trial without drug and without device

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • subjective cognitive decline, defined as self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event; normal performance on standardised cognitive tests adjusted for age, sex, and education; decline cannot be explained by psychiatric or other neurologic disease, medical disorder, medication, or substance use; no functional impact on daily life activities
  • mild cognitive decline, defined as persistent decline in cognitive performance (in comparison with a previous status) reported by the subject or by an informed caregiver; or observed by change on longitudinal cognitive testing; cognitive performance below expected range for that individual based on cognitive test performance (adjusted for age, sex, and education); performs daily life activities independently (but cognitive difficulty may result in detectable but minimal functional impact on the more complex activities of daily life, either self-reported or corroborated by a study partner); Clinical Dementia Rating Scale = 0.5
  • Ability to sign and understand the informed consent form

Exclusion criteria

  • Age under 50 or over 85 years
  • Non-native Italian speakers
  • Non degenerative and secondary forms of dementia
  • Previous or current participation in clinical trials with anti-amyloid agents

Treatment and study plan

Neuropsychological Assessments and Other Questionnaires

Diagnostic Test

A brief assessment of the cognitive status will be performed by the means of Mini-Mental State Examination (MMSE), Clinical Dementia Rating Scale (CDR-SB), Activities of the Daily Living (ADL) and Instrumental Activities of the Daily Living (IADL) scales. Moreover, extended neuropsychological assessments assessing memory, language, executive functions, attention and visuospatial perception will be conducted by trained neuropsychologists, as per clinical practice. Concerning depression and behavioural / neuropsychiatric symptoms, which are known to be relevant in cognitive decline and ageing, data will be collected by the means of Neuropsychiatric Inventory (NPI). Additional questionnaires about subjective cognitive decline, quality of sleep (Pittsburgh scale) and cognitive reserve (CRIq) will be conducted on some subgroups of subjects.

Blood Exams, Fluid Biomarkers, Genetics

Biological

All patients will undergo a blood samples collection at T0 and T4, as per clinical practice. Additional blood samples will be collected stored and processed according to literature recommendation-based standardized operating procedures.. Blood will be collected into EDTA tubes and will be immediately refrigerated and centrifugated at 2000x g for 10 minutes. Plasma will then be aliquoted in 0.5 ml polypropylene vials and frozen at -80°C. Levels of blood biomarkers of amyloidopathy, tauopathy, neurodegeneration and neuroinflammation will be measured using the Lumipulse G assays (Fujirebio) and the Multiplex assays for Ella (Biotechne). Whole blood samples will be used for genetic analysis, which will include the determination of APOE genotype

Connectivity Analysis

Other

Functional Magnetic Resonance Imaging (fMRI) and/or high-density electroencephalography (EEG) will be used to assess connectivity in selected group of subjects. EEG data will be collected during four 5-minute runs of alternating eyes-open and eyes-closed conditions using a 128-electrode high-density EEG system.

The EEG spectral coherence analysis will evaluate the functional coupling between the brain areas under study. Brain connectivity measures will be computed for each frequency band and for each subject, to be used as measure of weight of the graph in a graph analyses.

A subsample of subjects will be also investigated with connectivity measures of MRI by applying FA e DTI technique. All the data will be collected both at baseline and after a 2-years-period during which the prevention and intervention strategies will be performed.

Physical Activity

Device

Participants will be proposed an unsupervised, monitored exercise program consisting of three 60-minute sessions of moderate-intensity aerobic exercise (40%-85% of their maximum heart rate) each week. To track exercise intensity. The activity will be personalized according to specific attitude of each subjects including walking session, bike sessions or swim sessions. The type, frequency and intensity of the activity will be recorded by means of a commercially available wearables (Garmin Vivosmart 4, Garmin Vivosmart 5) and the Healthentia application. Those non using the wearables will keep a diary of the activity. Study investigators will ensure both protocol adherence and participant safety through regular follow-up telephone contacts.

Healthentia

Device

Healthentia, developed by Innovation Sprint, is a Software as a Medical Device (SaMD) designed for remote patient monitoring, virtual coaching, and automatic alerts using real-world data. It has been successfully used in over 20 studies and integrates features like teleconsultations, activity tracking, medication management, and support for wearable devices. It provides a patient companion app, offering remote patient monitoring and self-reporting, personalized advice or content in the form of dialogues. It is designed to optimize and improve patient engagement and ensure data integrity. The software facilitates daily self-reporting, providing information to patients and collecting other current data through self-reported questionnaires (health status, physical activity, quality of life, etc.), which will be crucial in order to control the adherence of patients to the program

Eligence

Device

Based Platform exercising the brain and the cognitive skills through 35+ games and activities designed by specialized health experts. It offers over 30 games focusing on cognitive skills such as memory, reasoning, attention, orientation, executive functions, construction skills, and language. It allows healthcare professionals to create personalized training sessions, monitor performance in real-time, and generate detailed evaluation reports. Accessible from any device, it is aimed at individuals in early stages of dementia or rehabilitation phases. In our clinical study, subjects will be trained on seven cognitive programs, which can be executed at home with or without assistance and supervision of a Health Professional (who can easily create personalized sessions to follow-up at distance) and/or an informal carer

Nutrition

Other

Participants will follow a personalized nutrition plan, as per clinical practice, receiving dietary advice derived by the same scheme already used in the FINGER project on prevention. The plan focuses on balanced, nutrient-rich meals, based on the reduction of carbohydrate assumption and stable inclusion of seeds, vegetables, fish and omega 3 aliments in the diet that may protect the brain through anti-inflammatory and antioxidant properties. A diary of the meals will be recorded in a diary included in the Healthentia application. No integrated meals or nutraceutical product will be used.

Primary outcomes

  1. Changes in cognitive performance and quality of life through cognitive scales (MiniMental State Examination)

    Time frame: after 36 months

    Statistically significant differences in changes in cognitive performance and quality of life after a 2-year intervention period, stratified by clinical, genetic, connectivity, and/or biomarker profiles through cognitive scales as MiniMental State Examination.

  2. Changes in cognitive performance and quality of life through cognitive scales (Clinical Dementia Rating Scale)

    Time frame: after 36 months

    Statistically significant differences in changes in cognitive performance and quality of life after a 2-year intervention period, stratified by clinical, genetic, connectivity, and/or biomarker profiles through cognitive scale as Clinical Dementia Rating Scale (CDR-SB).

  3. Changes in cognitive performance and quality of life through cognitive scales (Activities of the Daily Living)

    Time frame: after 36 months

    Statistically significant differences in changes in cognitive performance and quality of life after a 2-year intervention period, stratified by clinical, genetic, connectivity, and/or biomarker profiles through cognitive scale as Activities of the Daily Living (ADL).

  4. Changes in cognitive performance and quality of life through cognitive scales (Instrumental activities of the daily living)

    Time frame: after 36 months

    Statistically significant differences in changes in cognitive performance and quality of life after a 2-year intervention period, stratified by clinical, genetic, connectivity, and/or biomarker profiles through cognitive scale as Instrumental Activities of the Daily Living (IADL) scales.

  5. Changes in cognitive performance and quality of life through questionnaires (Quality of sleep)

    Time frame: after 36 months

    Statistically significant differences in changes in cognitive performance and quality of life after a 2-year intervention period, stratified by clinical, genetic, connectivity, and/or biomarker profiles through questionnaire as the quality of sleep (Pittsburgh scale).

  6. Changes in cognitive performance and quality of life through questionnaires (Cognitive reserve)

    Time frame: after 36 months

    Statistically significant differences in changes in cognitive performance and quality of life after a 2-year intervention period, stratified by clinical, genetic, connectivity, and/or biomarker profiles through questionnaires as the cognitive reserve (CRIq).

Secondary outcomes

  1. Measure of improvement in cognitive functioning

    Time frame: after 36 months

    A greater than 20% improvement in cognitive functioning, as measured by standardized cognitive assessment tool as MiniMental State Examination, after a 2-year intervention period

  2. Measure of improvement in cognitive functioning

    Time frame: after 36 months

    A greater than 20% improvement in cognitive functioning, as measured by standardized cognitive assessment tool as MontReal Cognitive Assessment (MOCA), after a 2-year intervention period

  3. Measure of improvement in quality of life

    Time frame: after 36 months

    A greater than 35% improvement in quality of life, assessed through validated questionnaire as quality of sleep (Pittsburgh scale), following the 2-year intervention period

  4. Measure of improvement in quality of life

    Time frame: after 36 months

    A greater than 35% improvement in quality of life, assessed through validated questionnaire as cognitive reserve (CRIq), following the 2-year intervention period

  5. inflammatory blood biomarker levels

    Time frame: after 36 months

    Measurable and clinically relevant changes in AD neurodegenerative and inflammatory blood biomarker levels after the 2-year intervention period, correlating these changes with cognitive outcomes

  6. Measure of improvement in user satisfaction

    Time frame: after 36 months

    A greater than 45% improvement in user satisfaction and interaction with the novel tools and interventions, as measured by satisfaction questionnaire , after the 2-year intervention period

  7. Measure of changes in brain connectivity

    Time frame: after 36 months

    Measurable and clinically relevant changes in brain connectivity as resulted by electroencephalography (EEG) analyses after the 2-year intervention period, correlating these changes with cognitive outcomes.

    Regarding EEG analysis, data will be acquired during four successive 5-min runs of alternating eyes-open and eyes-closed conditions using a high-density EEG (128 cephalic electrodes). Frequency bands of interest will be delta (2-4 Hz), theta (4-8 Hz), alpha1 (8-10.5 Hz), alpha2 (10.5-13 Hz), beta1 (13-20 Hz), beta2 (20-30 Hz) and gamma (30-40 Hz).

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Official study title

Comfortage - Integration of Biomarkers, Genetic and Clinical Risk Factors for AD Prevention Strategies

Acronym: Comfortage-P4

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Mar 26, 2025
Registry last updated
Aug 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.